media release

Akzo Nobel Reconfirms Listing of Organon BioSciences

PRESS RELEASE: Akzo Nobel has reconfirmed that it remains committed to its preferred route of a separate listing of Organon BioSciences.

Arnhem, the Netherlands, January 25, 2007 — Akzo Nobel has previously announced its intention to separate its Pharma business, preferably through a listing of approximately 20 to 30 percent of Organon BioSciences shares on Euronext in Amsterdam in early 2007.

Over the last few weeks, Akzo Nobel has received preliminary expressions of interest from a number of parties regarding an acquisition of Organon BioSciences.

Nobel has carefully reviewed these preliminary proposals from the perspective of long-term shareholder value creation. Taking into consideration the interests of all stakeholders, the company reconfirms that it remains committed to its preferred route of a separate listing of Organon BioSciences.

a result, Akzo Nobel has decided not to divert any resources away from pursuing the listing of Organon BioSciences within the original timeline.

related to the Proposed Separation
document does not constitute an offer of securities for sale in the United States of America or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make such offer or solicitation. Securities may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended.
Organon Biosciences N.V. nor Akzo Nobel N.V. intends to register any portion of the offering in the United States or conduct a public offering of shares of Organon Biosciences N.V. in the United States.

announcement is not an offer to sell or a solicitation of an offer to buy the ordinary shares of Organon Biosciences N.V. in the Netherlands. Any offer to acquire such securities will be made, and any investor should make his investment decision, solely on the basis of the information contained in the prospectus to be made generally available in the Netherlands in connection with the proposed offering.

Contact for this publication

Contact for other questions